N/A N=360 Alcohol Metabolism and Disease Risk in Asians
Healthy
Primary: Peak Number of Alcohol Drinks Consumed in a Day — 3.7; 4.2; 3.4; 3.0 drinks — p=.81
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Effect of Cryotherapy on Post-endodontic Pain
Cryotherapy
Primary: The Level of Post-endodontic Pain — 1.85; 2.15; 3.65 score on a scale — p=0.986
Phase 2 N=87 A Study of AZD8233 in Participants With Dyslipidemia.
Dyslipidemia
Primary: Part B: Change in LDL-C in Serum at Week 12 — 0.198; 0.458; 0.953 Ratio
N/A N=285,304 Sustaining Patient-centered Alcohol-related Care
Alcohol, Drinking · Alcohol Use Disorder
Primary: Brief Alcohol Counseling Rate — 57; 11 participants per 10,000 with visits — p=<.001
Phase 2 N=31 Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)
Glomerulonephritis, Membranous · antiPLA2R Positive
Primary: Number of Participants With Adverse Events — 15; 12 Participants
Phase 1 N=40 GLS-5700 in Dengue Virus-Naïve Adults
Healthy
Primary: Number of Participants With Serious Adverse Events From Day 0 Through Week 60 — 0; 0 participants
N/A N=11 Accuracy of Pulse Oximeters With Profound Hypoxia At Rest (NIHO17)
Hypoxia
Primary: Accuracy of Sensor Oxygen Saturation by Arms Calculation — 2.0 percentage of SpO2
N/A N=12 Inflammation and Protein Restriction
Protein Restriction · Diet · Inflammation
Primary: Changes in the Human Intestinal Microbiome That Result From Short Term Dietary Adjustment. — 232; 172; 145; 93 Number of immunity related genes — p=0.05
Phase 1 N=100 Regadenoson R-T Perfusion Imaging Trial
Coronary Artery Disease · Myocardial Perfusion Abnormalities
Primary: Detection of Coronary Artery Disease With Real-time Perfusion Echocardiography During Regadenoson Stress — 98; 98 Participants — p=<0.001
N/A N=11 Accuracy of Pulse Oximeters With Profound Hypoxia At Rest (NIHO16)
Hypoxia
Primary: Accuracy of Sensor Oxygen Saturation by Arms Calculation — 2.0 percentage of SpO2
N/A N=60 Impact of Reduced Cannabis Use on Functional Outcomes (R33 Phase)
Cannabis · Cannabis Use
Primary: Change in Mental Health Symptoms — -0.02; 0.11 score on a scale
Phase 4 N=381 Phase 4 COPD and Suboptimal Inspiratory Flow Rate
Chronic Obstructive Pulmonary Disease
Primary: FEV1 — 101; 78 mL — p=0.22
N/A N=106 QL vs PENG for Analgesia After Hip Arthroplasty
Block · Hip Replacement · Postoperative Pain
Primary: Postoperative Cumulative Opioid Consumption — 12.7; 9.9; 29.4; 23.2 morphine milligram equivalents
N/A N=43 Measurement and Modification of Threat Interpretation Bias in Neurodegenerative Movement Disorders (Aims 2 & 3)
Huntington Disease · Parkinson Disease
Primary: Proportion of Participants Completing at Least 50% of the MindTrails Sessions — 14; 14 Participants
Phase 2 N=36 A Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac Echocardiography
Cardiac Disease
Primary: 12-lead ECGs — 393.9; 392.0; 386.3; 2.8 millisecond